Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


DIREVO Biotech acquired by Bayer HealthCare
210 million EUR (approx. $300 million) transaction value


Cologne (Germany), September 16, 2008 – DIREVO Biotech AG announced today its acquisition by Bayer HealthCare in an all cash deal at a transaction value of €210 Million (approx. $300 Million). DIREVO Industrial Biotechnology GmbH, a wholly owned subsidiary of DIREVO Biotech AG, is not subject to this transaction and has been sold in a separate deal to a group of financial investors.

DIREVO Biotech’s unique and proprietary protein engineering platform uses high throughput technologies for the rapid discovery and optimization of biopharmaceuticals. The platform has already been successfully applied to a wide range of proteins, including therapeutic antibodies and proteases that will be added to the preclinical pipeline of Bayer Schering Pharma.

Bayer Healthcare plans to integrate DIREVO Biotech’s research and development (R&D) personnel into Bayer Schering Pharma’s global drug discovery organization. The site in Cologne will be maintained and integrated into Bayer Schering Pharma as a center of expertise for biologicals alongside the global R&D centers in Germany (Berlin and Wuppertal) and the USA (Berkeley).

”With this deal we emphasize our position as a recognized leader in protein engineering. Bayer HealthCare is our new owner of choice not only because of the excellent perspectives for our projects but also due to the close geographic proximity,” said Thomas von Rüden, CEO of DIREVO Biotech AG. “We feel that this is in the best interest of our former owners and our employees. As part of Bayer Schering Pharma we will further develop our expertise and knowledge in biopharmaceutical research.”

“Today Bayer Schering Pharma is among the top ten biologics companies in the world. We are committed to further strengthen our biologicals portfolio, and DIREVO’s leadership in protein engineering provides promising opportunities for further business growth,” said Arthur Higgins, CEO of Bayer HealthCare AG.

DIREVO was advised by Mummert & Company Corporate Finance GesmbH and Mayer Brown LLP.

About DIREVO Biotech AG

DIREVO Biotech AG generates superior bioengineered products and processes for industrial and pharmaceutical markets by enhancing nature's potential. The Company’s portfolio includes optimized proteins, optimized bioprocesses and other bio-molecules, to be used in research, in commercial development and on the market. DIREVO develops products both independently and with global leaders such as Danisco/Genencor, Nestlé, AstraZeneca/MedImmune and Pfizer. DIREVO Biotech is committed to a tailored approach to addressing customer needs and market opportunities.

DIREVO’s biopharmaceutical business generates improved second generation therapeutics and discovers and optimizes novel first-generation therapeutics in particular in the areas therapeutic antibody and protease. The core technology is a unique and repeatedly proven platform for discovery and optimization of a wide range of protein therapeutics. The company announced recently the implementation of a novel proprietary technology platform bestMab™ for the optimization of therapeutic antibodies. In addition, DIREVO is in the process of generating a 3rd generation fully human antibody library that, as the bestMab™ technology, is independent from any display technologies. Furthermore, DIREVO has successfully established a high-throughput protein engineering technology in mammalian cells that enables the optimization of complex proteins.

DIREVO has been financed by institutional investors, including TVM Capital, Bankhaus Wölbern, Danisco A/S/Danisco Venture, Mulligan BioCapital, Signet Healthcare Partners, NRW.Bank, and SKB Kapitalbeteiligungsgesellschaft mbH, a Sparkasse KölnBonn affiliated private equity firm as well as a number of private individuals.

Find more information at www.DIREVO.com


Contact:

DIREVO Biotech AG
Dr. Thomas von Rüden
CEO
t: + 49 221 8887-121
e: pr@DIREVO.com


College Hill Life Sciences
Dr. Robert Mayer
Account Manager
t: + 49 89 5238 8030
e: robert.mayer@collegehill.com


Publisher Contact Information:

Direvo
+ 49 221 8887-121
pr@DIREVO.com

Company profile of Direvo (acquired by Bayer HealthCare)
Past press releases of Direvo (acquired by Bayer HealthCare).

Data


25,720
Tech investments
From our Online Data Service
16,652
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
May 17€4.0MBiopharmaceuticals
May 16€15.0MPayment software
May 16€4.0MInternet services
May 16€80.0MConsumer electronics
May 16€6.3MImaging
May 16€13.0MInternet services
May 16€34.5MBiotechnology

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

Aug 17
Komed Health
komed health closes seed financing round





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.